Budesonide formoterol fumarate dihydrate
Pro Research Analysisby 
Searched over 200M research papers
Budesonide Formoterol Fumarate Dihydrate: Efficacy, Safety, and Pharmacokinetics
Introduction to Budesonide Formoterol Fumarate Dihydrate
Budesonide and formoterol fumarate dihydrate are commonly used in combination for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This combination leverages the anti-inflammatory properties of budesonide and the bronchodilatory effects of formoterol to manage respiratory conditions effectively.
Pharmacokinetics and Safety Profiles
Pharmacokinetics in Healthy Adults
A phase 1, randomized, single-dose, crossover study compared the pharmacokinetics (PK) and safety profiles of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF MDI) and budesonide/formoterol fumarate dihydrate (BFF MDI) with an active comparator in healthy adults. The study found that systemic exposure to budesonide and formoterol was higher for BGF MDI and BFF MDI compared to the dry powder inhaler (DPI) form, but all treatments were well tolerated with no significant differences in adverse events .
Pharmacokinetics in Chinese Adults
In a study involving healthy Chinese adults, the PK and safety profiles of BGF MDI and glycopyrronium/formoterol fumarate dihydrate (GFF MDI) were assessed. The results indicated that the addition of budesonide did not significantly alter the PK properties of GFF MDI. Both treatments were well tolerated, with mild adverse events reported .
Pharmacokinetics in Japanese Adults
A study on Japanese adults assessed the safety and PK profiles of BGF MDI. The findings showed that the systemic exposure to budesonide was dose-proportional, and the safety profile was comparable to that observed in Western populations, suggesting similar efficacy and safety across different ethnic groups .
Efficacy in COPD Treatment
Lung Function and Exacerbations
The TELOS study evaluated the efficacy of BFF MDI in patients with moderate to very severe COPD. The study demonstrated significant improvements in lung function and a reduction in the rate of moderate/severe exacerbations compared to monocomponents and an active comparator Ferguson2018Ferguson2018. Another study confirmed that BGF MDI improved lung function and reduced exacerbations across different blood eosinophil ranges, supporting its use in a broad patient population .
Cost-Effectiveness
An analysis using data from the ETHOS study estimated the long-term cost-effectiveness of BGF compared to dual therapies in the UK. The study concluded that BGF was cost-effective, primarily due to its ability to reduce exacerbation rates, which in turn reduced healthcare costs and improved quality of life .
Device Considerations
Metered Dose Inhaler vs. Dry Powder Inhaler
A study comparing the efficacy of budesonide/formoterol fumarate dihydrate delivered via a metered dose inhaler (MDI) with a spacer versus a dry powder inhaler (DPI) in patients with COPD and low peak inspiratory flow found no clinically meaningful differences in lung function improvements between the two devices. This suggests that both delivery methods are effective, even in patients with compromised inspiratory capacity .
Conclusion
Budesonide/formoterol fumarate dihydrate, whether used alone or in combination with glycopyrronium, has demonstrated significant efficacy in improving lung function and reducing exacerbations in patients with asthma and COPD. The pharmacokinetic profiles are consistent across different populations, and the treatments are generally well tolerated. Additionally, the combination therapy is cost-effective, making it a viable option for long-term management of respiratory conditions.
Sources and full results
Most relevant research papers on this topic